Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MADISON, Wis. , Dec. 7, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program.

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

Ardelyx

Oric Pharmaceuticals

In the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. These stocks highlight the trend of focusing on genetic and molecular characteristics, promising more effective healthcare solutions.

3 Stocks at the Forefront of Personalized Medicine Trend

Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.

Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?

Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates New concordance analysis supporting the generation of Oncotype DX® results from core needle biopsy to personalize treatment decisions ADAPTcycle trial data, using Oncotype DX results and endocrine response to stratify patients, may expand the number of breast cancer patients able to forgo chemotherapy post-surgery; data chosen as late-breaking abstract Prospective trial data regarding the potential omission of radiation therapy after surgery in certain patients with ductal carcinoma in situ (DCIS) chosen for press program MADISON, Wis., Nov. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium (SABCS).

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Fulgent Genetics

23andMe

If you're searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of healthcare.

The 3 Best Digital Health Stocks for Personalized Medicine

Agilent Technologies

Soleno Therapeutics

In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, but also have potential for future growth.

3 Biotech Stocks With Big-Time Breakthrough Potential

The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 51.73% Upside in Exact Sciences (EXAS): Can the Stock Really Move This High?

Airbnb

Exact Sciences' cancer testing platform could continue to do well through the end of the decade. Airbnb helps make traveling, one of people's favorite activities, easier and more enjoyable.

2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030

Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis. , Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware.

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

Shoals Technologies Group

Stem, Inc

Multi-billionaire investor Ken Fisher wrote recently that the stocks of relatively small companies tend to be very unpopular with the Street during the early phase of bull markets. Therefore, Fisher's advice at this point in the cycle is that investors buy only large-cap firms.

3 Stocks to Love Despite All of the Wall Street Hate

From a technical perspective, Exact Sciences (EXAS) is looking like an interesting pick, as it just reached a key level of support. EXAS recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.

Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises

Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Kevin Conroy - Chairman, Chief Executive Officer Jeff Elliott - Chief Financial Officer Everett Cunningham - Chief Commercial Officer Erik Holznecht - Manager, Investor Relations Conference Call Participants Catherine Schulte - Baird Brandon Couillard - Jefferies Derik de Bruin - Bank of America Dan Brennan - TD Cowen Andrew Brackmann - William Blair Vijay Kumar - Evercore ISI Matt Sykes - Goldman Sachs Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Dan Arias - Stifel Dan Leonard - UBS Mark Massaro - BTIG Kyle Mikson - Canaccord Eve Burstein - Burstein Albert Hu - Craig-Hallum Operator Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode, and please be advised that this call is being recorded.

Exact Sciences Corporation (EXAS) Q3 2023 Earnings Call Transcript

Reports record revenue, delivers more than a million test results, raises full-year guidance Third -quarter 2023 highlights Total third quarter revenue of $628 million, an increase of 20%, or 23% on a core revenue basis Delivered more than 1 million test results, including a record for Cologuard® and Oncotype DX® tests Full-year 2023 revenue and adjusted EBITDA guidance midpoints raised by $28 million and $25 million, respectively MADISON, Wis. , Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $628.3 million for the third quarter ended September 30, 2023, compared to $523.1 million for the same period of 2022.

Exact Sciences Announces Third-Quarter 2023 Results

MADISON, Wis. , Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Exact Sciences to participate in November investor conferences

General Motors

Many investors are probably upset that the yields of the 10-year treasury bonds are trading around 5%. It's true that higher bond yields do increases companies' borrowing costs and make stocks less attractive.

3 Comeback Stocks to Buy Before They Soar Again in 2024

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for next-generation Cologuard test expected to minimize unnecessary follow-up colonoscopies, supporting positive patient experiences1 MADISON, Wis. , Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer (CRC) at 91% specificity, during the American College of Gastroenterology (ACG) Annual Meeting 2023.

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection

MADISON, Wis. , Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical Oncology (ESMO) Congress, October 20-24, in Madrid, Spain.

Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress

Axon Enterprise

First Solar

MGM Resorts

Plug Power

Rivian Automotive

Super Micro Computer

With inflation under control, and economic growth still strong, there should be plenty of winning stocks between now and the end of the year. In fact, consider this.

7 Winning Stocks That Will Make You an Investing Champion

UiPath

Zoom Video

At the end of September, Cathie Wood sat down with Morningstar to discuss the current and future state of Ark Invest, including the investment management firm's flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ). In the interview, the host noted one apparent misstep.

Cathie Wood's 3 Favorite AI Stocks: October 2023

Boston Scientific

CareTrust REIT

Life Time Group Holdings

Topgolf Callaway Brands Corp

Novo Nordisk

Royal Caribbean Cruises

There's no doubt that America is aging. The numbers do not lie.

7 Affordable Stocks to Invest in as America's Population Ages

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023.

Exact Sciences schedules third quarter 2023 earnings call

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking data on next-generation Cologuard® from the BLUE-C pivotal trial during the American College of Gastroenterology (ACG) Annual Meeting, taking place October 20-25, 2023, in Vancouver, Canada.

Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023

Guardant Health Inc

Exact Sciences and Guardant Health have both enjoyed triple-digit revenue growth over the past five years. Exact Sciences' shares are up more than 31% so far this year, while Guardant is up a little more than 5%.

News for Exact Sciences Stock (EXAS)